EMAIL THIS PAGE TO A FRIEND

Journal of virology

Permissiveness of human cancer cells to oncolytic bovine herpesvirus 1 is mediated in part by KRAS activity.


PMID 24696490

Abstract

Oncolytic viruses (OVs) are attractive avenues of cancer therapy due to the absence of toxic side effects often seen with current treatment modalities. Bovine herpesvirus 1 (BHV-1) is a species-specific virus that does not induce cytotoxicity in normal primary human cells but can infect and kill various human immortalized and transformed cell lines. To gain a better understanding of the oncolytic breadth of BHV-1, the NCI panel of established human tumor cell lines was screened for sensitivity to the virus. Overall, 72% of the panel is permissive to BHV-1 infection, with corresponding decreases in cellular viability. This sensitivity is in comparison to a sensitivity of only 32% for a herpes simplex virus 1 (HSV-1)-based oncolytic vector. Strikingly, while 35% of the panel supports minimal or no BHV-1 replication, significant decreases in cellular viability still occur. These data suggest that BHV-1 is an OV with tropism for multiple tumor types and is able to induce cytotoxicity independent of significant virus replication. In contrast to other species-specific OVs, cellular sensitivity to BHV-1 does not correlate with type I interferon (IFN) signaling; however, mutations in KRAS were found to correlate with high levels of virus replication. The knockdown or overexpression of KRAS in human tumor cell lines yields modest changes in viral titers; however, overexpression of KRAS in normal primary cells elicits permissivity to BHV-1 infection. Together, these data suggest that BHV-1 is a broad-spectrum OV with a distinct mechanism of tumor targeting. Cancer remains a significant health issue, and novel treatments are required, particularly for tumors that are refractory to conventional therapies. Oncolytic viruses are a novel platform given their ability to specifically target tumor cells while leaving healthy cells intact. For this strategy to be successful, a fundamental understanding of virus-host interactions is required. We previously identified bovine herpesvirus 1 as a novel oncolytic virus with many unique and clinically relevant features. Here, we show that BHV-1 can target a wide range of human cancer types, most potently lung cancer. In addition, we show that enhanced KRAS activity, a hallmark of many cancers, is one of the factors that increases BHV-1 oncolytic capacity. These findings hold potential for future treatments, particularly in the context of lung cancer, where KRAS mutations are a negative predictor of treatment efficacy.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A5474
L-Aspartic acid, PharmaGrade, Ajinomoto, EP, JP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture
C4H7NO4
A9256
L-Aspartic acid, reagent grade, ≥98% (HPLC)
C4H7NO4
A8949
L-Aspartic acid, BioXtra, ≥99% (HPLC)
C4H7NO4
A7219
L-Aspartic acid, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
C4H7NO4
A4534
L-Aspartic acid, BioReagent, suitable for cell culture, suitable for insect cell culture
C4H7NO4
11189
L-Aspartic acid, BioUltra, ≥99.5% (T)
C4H7NO4
PHR1104
L-Aspartic acid, Pharmaceutical Secondary Standard; Certified Reference Material
C4H7NO4
W365601
L-Aspartic acid, ≥98%, FG
C4H7NO4
51572
L-Aspartic acid, certified reference material, TraceCERT®
C4H7NO4
S4500
L-Serine, ReagentPlus®, ≥99% (HPLC)
C3H7NO3
RES0908S-A7
L-Serine, PharmaGrade, Ajinomoto, EP, USP, JP, Manufactured under appropriate controls for use in pharma or biopharmaceutical production, suitable for cell culture
C3H7NO3
S4311
L-Serine, from non-animal source, meets EP, USP testing specifications, suitable for cell culture, 98.5-101.0%
C3H7NO3
84959
L-Serine, BioUltra, ≥99.5% (NT)
C3H7NO3
54763
L-Serine, certified reference material, TraceCERT®
C3H7NO3
84960
L-Serine, ≥99.0% (NT)
C3H7NO3
78682
L-Serine, tested according to Ph.Eur.
C3H7NO3
PHR1103
L-Serine, Pharmaceutical Secondary Standard; Certified Reference Material
C3H7NO3
S1315
L-Serine, PharmaGrade, Ajinomoto, EP, USP, manufactured under appropriate GMP controls for Pharma or Biopharmaceutical production, suitable for cell culture
C3H7NO3